Motley Fool Asset Management LLC Sells 9,800 Shares of Moderna, Inc. (NASDAQ:MRNA)

Motley Fool Asset Management LLC reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 63.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,668 shares of the company's stock after selling 9,800 shares during the quarter. Motley Fool Asset Management LLC's holdings in Moderna were worth $236,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB increased its stake in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new position in shares of Moderna during the fourth quarter worth approximately $37,000. Venturi Wealth Management LLC grew its stake in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in shares of Moderna during the 4th quarter worth $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Price Performance

NASDAQ:MRNA traded up $2.03 during mid-day trading on Wednesday, reaching $26.67. The stock had a trading volume of 13,082,139 shares, compared to its average volume of 7,113,632. The business's 50 day moving average is $31.96 and its 200 day moving average is $41.54. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The stock has a market cap of $10.31 billion, a P/E ratio of -2.87 and a beta of 2.23.

Remove Ads

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Citigroup initiated coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective for the company. Leerink Partners dropped their target price on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research report on Thursday, January 16th. Morgan Stanley lowered their price target on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday. Bank of America reduced their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Finally, Argus cut Moderna from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $58.70.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.